Atypical Antipsychotic: Indications, Adverse Effects and Market Analysis
Published Date : Aug-26 ID: CVC-29459 Format: PDF Pages: 300
Report Highlights
According to a research survey conducted by ChemView Consulting, the Atypical Antipsychotic Market was worth US$ 16.61 Bn. The market is expected to grow at a CAGR of 6.90% between 2023 and 2033 to hit US$ 32.38 Bn by 2033 end.
Research Scope/Taxonomy
Market Analysis by Drug Class:
Market Analysis by Indication:
Market Analysis by Distribution Channel:
Key Companies Profiled
1.1. Global Market Snapshot
1.2. Key Success Factors
1.3. Strategic Analysis and Recommendations
2.1. Market Taxonomy
2.2. Market Definitions
3.1. Preliminary Investigation & Research Design
3.2. Secondary Research & Primary Research
3.3. Data Analysis & Econometric Modelling
3.4. Expert Data Validation
4.1. Supply-Side Trends
4.2. Demand-Side Trends
5.1. Global Market Value (US$ Mn) Analysis, 2017 – 2032
5.2. Incremental $ Opportunity Index, 2022-2032
5.3. Global Market Volume (Tons) Analysis, 2017 – 2032
6.1. Regional Level Pricing Analysis and Forecast
6.1.1. Manufacturers Level Pricing
6.1.2. Distributor Level Pricing
6.2. Global Pricing Analysis Benchmark
6.3. Cost Breakdown Analysis
7.1. Cross Analysis of Application W.R.T. Product Type
8.1. Regional Supply Vs. Demand Gap Assessment
8.2. Top Producing Countries Analysis
9.1. Macroeconomic Factors
9.2. Forecast Factors
9.3. Market Dynamics
9.3.1. Driver
9.3.2. Restraint
9.3.3. Opportunity
9.4. Supply Chain Analysis
9.4.1. List Raw Material Suppliers
9.4.2. List of Manufacturers
9.4.3. List of Distributors
9.4.4. List of End-Users
9.4.5. End-Users Consumption Analysis
9.4.6. Average Profitability Margin Analysis
9.5. Covid-19 Impact Assessment
9.5.1. Economy/Cluster Projections
9.5.2. Covid-19 Economic Assessment
9.5.3. Impact on Target Market
9.5.4. Recovery Scenario
9.6. Regulatory Framework
9.6.1. Regulations of Key Countries
9.6.2. Potential Impact of Regulations
9.7. Porter’s Five Forces Analysis
9.8. Technology Landscape
10.1. Introduction
10.2. Key Market Trends
10.3. Historical and Current Market (2017-2021) and Future Market Analysis (2022-2032) By Drug Class [Value (US$ Mn) and Volume (Tons) Analysis]
10.3.1. Risperidone
10.3.2. Olanzapine
10.3.3. Quetiapine
10.3.4. Ziprasidone
10.3.5. Aripiprazole
10.3.6. Paliperidone
10.3.7. Lurasidone
10.4. Market Attractiveness Analysis by Drug Class
11.1. Introduction
11.2. Historical and Current Market (2017-2021) and Future Market Analysis (2022-2032) By Indication [Value (US$ Mn) and Volume (Tons) Analysis]
11.2.1. Bipolar I Disorder
11.2.2. Schizophrenia
11.2.3. Schizoaffective Disorder
11.2.4. Major Depressive Disorder (MDD)
11.3. Market Attractiveness Analysis by Application
12.1. Introduction
12.2. Historical and Current Market (2017-2021) and Future Market Analysis (2022-2032) By Distribution Channel [Value (US$ Mn) and Volume (Tons) Analysis]
12.2.1. Hospital Pharmacy
12.2.2. Retail Pharmacy
12.2.3. Drug Store
12.2.4. E-commerce
12.2.5. Others
12.3. Market Attractiveness Analysis by End-Use Industry
13.1. Introduction
13.2. Key Market Trends
13.3. Historical and Current Market (2017-2021) and Future Market Analysis (2022-2032) By Region [Value (US$ Mn) and Volume (Tons) Analysis]
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. Asia-Pacific
13.3.5. Middle East
13.3.6. Africa
13.4. Market Attractiveness Analysis by Region
14.1. Introduction
14.2. Key Market Trends
14.3. Historical and Current Market Size (2017-2021) and Future Market Size Analysis (2022-2032) [Value (US$ Mn) and Volume (Tons) Analysis]
14.3.1. By Country
14.3.1.1. U.S.
14.3.1.2. Canada
14.3.2. By Drug Class
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Indication
14.4.4. By Distribution Channel
15.1. Introduction
15.2. Key Market Trends
15.3. Historical and Current Market Size (2017-2021) and Future Market Size Analysis (2022-2032) [Value (US$ Mn) and Volume (Tons) Analysis]
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Rest of Latin America
15.3.2. By Drug Class
15.3.3. By Indication
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Indication
15.4.4. By Distribution Channel
16.1. Introduction
16.2. Key Market Trends
16.3. Historical and Current Market Size (2017-2021) and Future Market Size Analysis (2022-2032) [Value (US$ Mn) and Volume (Tons) Analysis]
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. UK
16.3.1.5. Spain
16.3.1.6. Netherlands
16.3.1.7. Norway
16.3.1.8. Russia
16.3.1.9. Rest of Europe
16.3.2. By Drug Class
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Indication
16.4.4. By Distribution Channel
17.1. Introduction
17.2. Key Market Trends
17.3. Historical and Current Market Size (2017-2021) and Future Market Size Analysis (2022-2032) [Value (US$ Mn) and Volume (Tons) Analysis]
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.1.4. India
17.3.1.5. Indonesia
17.3.1.6. Thailand
17.3.1.7. Vietnam
17.3.1.8. Australia & New Zealand
17.3.1.9. Rest of Asia-Pacific
17.3.2. By Drug Class
17.3.3. By Indication
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Indication
17.4.4. By Distribution Channel
18.1. Introduction
18.2. Key Market Trends
18.3. Pricing Analysis
18.4. Historical and Current Market Size (2017-2021) and Future Market Size Analysis (2022-2032) [Value (US$ Mn) and Volume (Tons) Analysis]
18.4.1. By Country
18.4.1.1. Saudi Arabia
18.4.1.2. Turkey
18.4.1.3. U.A.E.
18.4.1.4. Rest of the Middle East
18.4.2. By Drug Class
18.4.3. By Indication
18.4.4. By Distribution Channel
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Drug Class
18.5.3. By Indication
18.5.4. By Distribution Channel
19.1. Introduction
19.2. Key Market Trends
19.3. Pricing Analysis
19.4. Historical and Current Market Size (2017-2021) and Future Market Size Analysis (2022-2032) [Value (US$ Mn) and Volume (Tons) Analysis]
19.4.1. By Country
19.4.1.1. South Africa
19.4.1.2. Nigeria
19.4.1.3. Egypt
19.4.1.4. Rest of Africa
19.4.2. By Drug Class
19.4.3. By Indication
19.4.4. By Distribution Channel
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Drug Class
19.5.3. By Indication
19.5.4. By Distribution Channel
20.1. Tier Structure Breakdown
20.2. Market Share Analysis
20.3. Production Capacity Analysis
20.4. Company Footprint Analysis
20.4.1. Product Footprint of Players
20.4.2. Regional Footprint of Players
20.4.3. Channel Footprint of Players
20.5. Brand Preference Analysis
20.6. Competition Dashboard
21.1. GlaxoSmithKline Plc
21.1.1. Company Overview
21.1.2. Product & Financial Portfolio
21.1.3. Manufacturing Facilities
21.1.4. Recent Developments
21.1.5. SWOT Analysis
21.1.6. Strategy Overview
21.2. Johnson and Johnson
21.3. Pfizer Inc.
21.4. Eil Lilly and Company
21.5. Bristol-Myers Squibb Company
21.6. Allergan Plc.
21.7. Cardinal Health Inc.
21.8. Sanis Health Inc.
21.9. Ranbaxy Inc. (Sun Pharmaceutical Industries Ltd.)
21.10. Novartis AG